Ozempic, Wegovy, and the Economy

Estimated reading time: 3 minutes

Carrying Weight

Ozempic and Wegovy may help patients lose weight. But the weight they carry in the economy is only increasing.

By 2030, some 48 million Americans will have shed a collective hundreds of millions of pounds thanks to these treatments, according to industry analysts. These projections have implications for both patients and the broader economy.

The Ozempic Effect

The popularity of Ozempic and Wegovy has already started to disrupt other treatment providers.

The producer of these drugs, pharmaceutical giant Novo Nordisk (NVO), recently stated semaglutide — the main ingredient in its weight-loss medications — could also help reduce kidney failure, according to a drug trial. This news sent the stocks of companies that produce kidney dialysis products, such as Fresenius Medical Care (FMS), plummeting.

Heavyweight Profits

Investors are rushing to figure out the impact of these drugs on the pharmaceutical industry and beyond.

Given Ozempic and Wegovy are appetite suppressants, some retailers, like Walmart (WMT), claim to already see an impact Beyond food, a slimmer American population might also lead to cost savings in the healthcare industry. Some have even estimated it could even help airlines save millions of dollars on jet fuel.

Investors who can effectively anticipate these changes could well see weighty profits.

Disclaimer
SoFi Securities (Hong Kong) Limited and its affiliates (SoFi HK) may post or share information and materials from time to time. They should not be regarded as an offer, solicitation, invitation, investment advice, recommendation to buy, sell or otherwise deal with any investment instrument or product in any jurisdictions. Keep in mind that investing involves risk, and past performance of an asset never guarantees future results or returns. It’s important for investors to consider their specific financial needs, goals, and risk profile before making an investment decision.
SoFi HK does not make any warranties about the completeness, reliability and accuracy of this information and will not be liable for any losses and/or damages in connection with the use of this information.
The information and materials may contain hyperlinks to other websites, we are not responsible for the content of any linked sites. The information and analysis provided through hyperlinks to third party websites, while believed to be accurate, cannot be guaranteed by SoFi HK. These links are provided for informational purposes and should not be viewed as an endorsement. The risk involved in using such hyperlinks shall be borne by the visitor and subject to any Terms of Use applicable to such access and use.
Any product, logos, brands, and other trademarks or images featured are the property of their respective trademark holders. These trademark holders are not affiliated with SoFi HK or its Affiliates. These trademark holders do not sponsor or endorse SoFi HK or any of its articles.
Without prior written approval of SoFi HK, the information/materials shall not be amended, duplicated, photocopied, transmitted, circulated, distributed or published in any manner, or be used for commercial or public purposes.